MLYS
Mineralys Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$21.24
−0.65%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 21.0K | — | — | — | — |
| Gross Profit | (21.0K) | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 301.6M | 132.0M | 168.6M | 70.4M | 26.3M |
| SG&A Expense | 69.2M | 38.6M | 23.8M | 14.3M | 5.2M |
| General & Admin Expense | 69.2M | 38.6M | 23.8M | 14.3M | 5.2M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 370.8M | 170.6M | 192.4M | 84.7M | 31.5M |
| Cost and Expenses | 370.8M | 170.6M | 192.4M | 84.7M | 31.5M |
| Operating Income (EBIT) | (370.8M) | (170.6M) | (192.4M) | (84.7M) | (31.5M) |
| Non-Operating | |||||
| Interest Income | 21.2M | 16.0M | 14.6M | 12.8M | 1.7M |
| Interest Expense | — | — | — | — | 1.7M |
| Net Interest Income | 21.2M | 16.0M | 14.6M | 12.8M | — |
| Other Non-Op Income/Expense | 21.2M | 16.0M | 14.6M | 12.8M | 1.7M |
| Non-Operating Income (excl Interest) | (21.2M) | (16.0M) | (14.6M) | (12.8M) | (3.4M) |
| EBT (Pre-Tax Income) | (349.6M) | (154.7M) | (177.8M) | (71.9M) | (29.8M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (349.6M) | (154.7M) | (177.8M) | (71.9M) | (29.8M) |
| Earnings from Cont. Ops | (349.6M) | (154.7M) | (177.8M) | (71.9M) | (29.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (349.6M) | (154.7M) | (177.8M) | (71.9M) | (29.8M) |
| Per Share | |||||
| Basic EPS | ($4.24) | ($2.29) | ($3.66) | ($1.99) | ($5.77) |
| Diluted EPS | ($4.24) | ($2.29) | ($3.66) | ($1.99) | ($5.77) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 84.7M | 67.7M | 48.5M | 36.2M | 5.2M |
| Diluted Shares Outstanding | 84.7M | 67.7M | 48.5M | 36.2M | 5.2M |
| Profitability Metrics | |||||
| EBITDA | (349.5M) | (154.6M) | (177.8M) | (71.9M) | (28.1M) |
| D&A | 39.0K | 59.0K | 43.0K | — | — |
| EBIT | (349.6M) | (154.7M) | (177.8M) | (71.9M) | (28.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026